

8. Menning CB. The noble hunt: the "Libro della caccia" of Angelo del Bufalo. *Yale Univ Libr Gaz*. 2001;76:27-35.
9. Fornaciari G, Giuffra V, Ferroglio E, Gino S, Bianucci R. *Plasmodium falciparum* immunodetection in bone remains of members of the Renaissance Medici family (Florence, Italy, sixteenth century). *Trans R Soc Trop Med Hyg*. 2010;104:583-7. <https://doi.org/10.1016/j.trstmh.2010.06.007>
10. Boualam MA, Pradines B, Drancourt M, Barbieri R. Malaria in Europe: a historical perspective. *Front Med*. 2021;8:691095. <https://doi.org/10.3389/fmed.2021.691095>

Address for correspondence: Albert Zink, Institute for Mummy Studies, Eurac Research, Viale Druso 1, 39100 Bolzano, Italy; email: albert.zink@eurac.edu

Enhanced Adenovirus Vaccine Safety Surveillance in Military Setting, United States

John Iskander, Scott Blanchet, Caitlin Springer, Patrick Rockwell, Dana Thomas, Satish Pillai

Author affiliations: United States Coast Guard, Washington, DC, USA (J. Iskander, D. Thomas, S. Pillai); United States Coast Guard Academy, New London, Connecticut, USA (S. Blanchet, C. Springer, P. Rockwell)

DOI: <https://doi.org/10.3201/eid2906.230331>

The US Coast Guard Academy began adenovirus vaccination of incoming cadets in 2022. Of 294 vaccine recipients, 15%–20% had mild respiratory or systemic symptoms within 10 days postvaccination but no serious adverse events after 90 days. Our findings support the continued use of adenovirus vaccines in congregate military settings.

Adenovirus infection results in considerable illness among congregate military populations (1). US Food and Drug Administration–approved use of a live, oral, bivalent adenovirus vaccine for military populations began in 2011 and was associated with substantial decreases in adenovirus infection incidence at US military basic training centers (2,3). The US Naval Academy introduced adenovirus vaccination in 2018 after a large adenovirus outbreak (4). An adenovirus outbreak involving ≈300 cadets occurred at the US

Coast Guard Academy (CGA) in 2019 (5). Adenovirus vaccines were introduced for incoming first-year CGA cadets on June 28, 2022. To supplement postlicensure data on adenovirus vaccine safety (6), we monitored postvaccination signs and symptoms in those cadets.

We developed a monitoring system to account for military training features, such as restricted cellphone access and a time-sensitive, regimented curriculum. For sick call visits occurring ≤10 days after vaccination, the CGA clinic used a monitoring tool (Appendix, <https://wwwnc.cdc.gov/EID/article/29/6/23-0331-App1.pdf>) consisting of 17 postvaccination signs or symptoms obtained from clinical trial results (7,8). We measured vaccine uptake and inability to swallow pills and monitored cadets for 90 days after vaccination for US Food and Drug Administration–defined serious adverse events (9).

Cadets received an in-person briefing from CGA clinic staff on June 27, 2022. The CGA training cadre, with whom the cadets had daily contact, were briefed by clinic leadership on the paper-based reporting tool, reporting requirements, and referring ill cadets to the CGA clinic. Before vaccination, cadets were given the Centers for Disease Control and Prevention adenovirus vaccine information statement and opportunity to ask questions. Subsequently, if cadets sought care for illness at the CGA clinic, staff used the reporting tool to record whether any of the 17 signs and symptoms were present.

During the initial vaccination period (June 28–30, 2022), 293 (97.3%) of 301 first-year cadets received the adenovirus vaccine; 4 (1.3%) cadets were unable to swallow the vaccine. Of 4 cadets isolated for COVID-19 during the initial vaccination period, only 1 subsequently received the vaccine. Of 294 vaccinated cadets, a total of 159 (54.1%) received 1 other vaccine and 53 (18.0%) received ≥2 additional vaccines.

The average age of the 294 vaccine recipients was 18.25 years; 57% were male, and 43% female. During June 30–July 8, 2022, ≈100 first-year cadets sought care at the CGA clinic for illness, and 65 (22.1%) cadets reported ≥1 vaccine surveillance sign or symptom. Commonly reported signs and symptoms were cough (20.1%), sore throat (17.0%), headache (16.0%), fatigue (16.0%), nasal congestion (15.3%), and shortness of breath (11.6%) (Table). Frequencies of gastrointestinal symptoms among cadets seeking care at the clinic during the 10-day period after vaccination were 2.3% for abdominal pain, 3.7% for diarrhea, 4.0% for vomiting, and 8.3% for nausea (Table). During the 90 days after vaccination, no serious adverse events were reported, including hospitalization, Guillain-Barre syndrome, or death.

Table. Percentages of first-year US Coast Guard cadets reporting signs or symptoms within 10 days after adenovirus vaccination in study of enhanced adenovirus vaccine safety surveillance in military setting, United States*

Signs or symptoms	% Total†
Cough	20.1
Sore throat	17.0
Headache	16.0
Fatigue	16.0
Nasal congestion or rhinorrhea	15.3
Shortness of breath	11.6
Arthralgias or myalgias	10.5
Nausea	8.5
Fever, subjective or measured at >38.0°C	7.8
Increasing weakness in arms or legs	5.8
Numbness or tingling in hands or feet	4.8
Vomiting	4.1
Diarrhea	3.7
Abdominal pain	2.4
New rash	0.7
Dysuria	0.0
Hematuria	0.0

*Total number of vaccinated cadets was 294.

†Percentages sum to >100% because vaccine recipients reported multiple signs or symptoms.

During the enhanced postimmunization monitoring period, a concomitant COVID-19 outbreak affected ≈20% of first-year cadets. Of the 65 students who sought care at the CGA clinic and had ≥1 enhanced surveillance sign or symptom, 8 (12.3%) also tested positive for COVID-19.

The live adenovirus vaccine was well-tolerated; only 4 vaccination failures occurred, the cadets who could not swallow the medication. Of 294 vaccinated CGA cadets, <25% reported signs or symptoms during the monitoring period. Phase 1 adenovirus vaccine trial data (7) showed symptom occurrence reached 33% within 8 weeks postvaccination. The most common signs and symptoms reported among CGA first-year cadets corresponded with those noted in a large phase 3 adenovirus trial (8), including headache, sore throat, nasal congestion, and cough. In this cohort, rates for gastrointestinal symptoms (2.3%–8.3%) were lower than those reported in the phase 3 trial (8).

Shortness of breath in 11.6% of cadets did not clearly correspond to signs and symptoms identified in phase 1 or phase 3 trial safety data. Given that >25% of nonhospitalized adults with COVID-19 report shortness of breath (10), the concurrent COVID-19 outbreak might have contributed to reports of this specific symptom.

In conclusion, enhanced passive monitoring established after introducing adenovirus vaccination for incoming first-year CGA cadets did not identify any serious adverse events. Even with the receipt of multiple vaccines and an intercurrent COVID-19 outbreak, the signs and symptoms profile among cadets who had sick calls during the 10-day postvaccination

period appears consistent with profiles reported in previous adenovirus vaccine trials. A positive COVID-19 test was observed for 12.3% of cadets who completed the surveillance questionnaire during their sick call, which might explain the 11.6% of cadets who reported shortness of breath. Our favorable real-world findings support continuing adenovirus vaccination of incoming CGA cadet classes and wider use of the vaccine in congregate military settings.

Acknowledgments

We thank Christopher Janik, Martin Newton, Garrett Heitmann, Benjamin Keller, Matthew Cuevas, Fahad Alsayyid, and Shane Steiner for providing logistic and technical support.

About the Author

Dr. Iskander is Chief of Preventive Medicine and Population Health for the United States Coast Guard in Washington, DC. His primary interests focus on immunization-related topics.

References

- McNeill KM, Ridgely Benton F, Monteith SC, Tuchscherer MA, Gaydos JC. Epidemic spread of adenovirus type 4-associated acute respiratory disease between U.S. Army installations. *Emerg Infect Dis.* 2000;6:415–9. <https://doi.org/10.3201/eid0604.000419>
- Radin JM, Hawksworth AW, Blair PJ, Faix DJ, Raman R, Russell KL, et al. Dramatic decline of respiratory illness among US military recruits after the renewed use of adenovirus vaccines. *Clin Infect Dis.* 2014;59:962–8. <https://doi.org/10.1093/cid/ciu507>
- O'Donnell FL, Taubman SB. Follow-up analysis of the incidence of acute respiratory infections among enlisted service members during their first year of military service before and after the 2011 resumption of adenovirus vaccination of basic trainees. *MSMR.* 2015;22:2–7.
- Rogers AE, Lu X, Killerby M, Campbell E, Gallus L, Kamau E, et al. Outbreak of acute respiratory illness associated with adenovirus type 4 at the U.S. Naval Academy, 2016. *MSMR.* 2019;26:21–7.
- Chu VT, Simon E, Lu X, Rockwell P, Abedi GR, Gardner C, et al. Outbreak of acute respiratory illness associated with human adenovirus type 4 at the United States Coast Guard Academy, 2019. *J Infect Dis.* 2022;225:55–64. <https://doi.org/10.1093/infdis/jiab322>
- McNeil MM, Paradowska-Stankiewicz I, Miller ER, Marquez PL, Seshadri S, Collins LC Jr, et al. Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS), United States, October 2011–July 2018. *Vaccine.* 2019;37:6760–7. <https://doi.org/10.1016/j.vaccine.2019.08.087>
- Lyons A, Longfield J, Kuschner R, Straight T, Binn L, Seriwatana J, et al. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. *Vaccine.* 2008;26:2890–8. <https://doi.org/10.1016/j.vaccine.2008.03.037>

8. Kuschner RA, Russell KL, Abuja M, Bauer KM, Faix DJ, Hait H, et al; Adenovirus Vaccine Efficacy Trial Consortium. A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits. *Vaccine*. 2013;31:2963–71. <https://doi.org/10.1016/j.vaccine.2013.04.035>
9. US Food and Drug Administration. CFR—Code of Federal Regulations Title 21, 21CFR312.32. Investigational new drug application [cited 2023 Apr 3]. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=312.32>
10. Burke RM, Killerby ME, Newton S, Ashworth CE, Berns AL, Brennan S, et al.; Case Investigation Form Working Group. Symptom profiles of a convenience sample of patients with COVID-19—United States, January–April 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69:904–8. <https://doi.org/10.15585/mmwr.mm6928a2>

Address for correspondence: John Iskander, United States Coast Guard Headquarters, 2703 Martin Luther King Jr Ave SE, Washington, DC 20593-7907, USA; email: John.K.Iskander@uscg.mil

Isolated Ocular Mpox without Skin Lesions, United States

Minh T. Nguyen, Akshay Mentreddy, Julie Schallhorn, Matilda Chan, Su Aung, Sarah B. Doernberg, Jennifer Babik, Kevin Miles, Katherine Yang, Emily Lydon, Daniel J. Minter, John Gonzales, Jessica Shantha, Thuy Doan, Gerami D. Seitzman

Author affiliations: University of California, San Francisco, California, USA (M.T. Nguyen, A. Mentreddy, J. Schallhorn, M. Chan, S. Aung, S.B. Doernberg, J. Babik, K. Miles, K. Yang, E. Lydon, D.J. Minter, J. Gonzales, J. Shantha, T. Doan, G.D. Seitzman); Francis I. Proctor Foundation, San Francisco (M.T. Nguyen, A. Mentreddy, M. Chan, J. Gonzales, J. Shantha, T. Doan, G.D. Seitzman)

DOI: <https://doi.org/10.3201/eid2906.230032>

We report a case of a 53-year-old HIV-negative patient in San Francisco, California, USA, with no classic mpox prodromal symptoms or skin lesions who experienced fulminant, vision-threatening scleritis, keratitis, and uveitis. Deep sequence analysis identified monkeypox virus RNA in the aqueous humor. We confirmed the virus on the cornea and sclera by PCR.

We report a case of ocular-only mpox infection in a 53-year-old man in San Francisco, California, USA. His medical history included chronic lymphocytic leukemia (CLL), inactive 2 years after treatment with obinutuzumab and venetoclax but with persistent lymphopenia. He reported male sexual partners but was HIV negative. Symptoms in his right eye began August 2022 as itching and nasal scleral redness (Figure, panel A). There was no fever, rash, or lymphadenopathy. Eye redness worsened; the patient sought care at an urgent care facility and was given erythromycin ointment. Continued vision loss led to an emergency department visit, resulting in a diagnosis of preseptal cellulitis, treated with trimethoprim/sulfamethoxazole plus amoxicillin/clavulanic acid.

In early September 2022, the patient sought care at a county eye clinic for purulent conjunctivitis and corneal epithelial defects. Clinicians suspected gonococcal conjunctivitis and administered intramuscular ceftriaxone and topical moxifloxacin 0.5%. Bacterial and fungal ocular cultures and herpetic viral PCR returned negative results. Topical prednisolone acetate 1% and oral valacyclovir failed to control the eye inflammation. Three weeks after initial symptoms appeared, the patient's ocular inflammation increased; keratic precipitates and a moderate corneal opacity developed. Uveitis and scleritis workups did not yield a specific diagnosis (Table).

In late September 2022, at a second opinion examination at a University of California clinic, the patient's right eye acuity was 20/640. Examination showed a nasal patch of avascular scleral necrosis (Figure, panel B), and corneal epithelial sloughing (Figure, panel C) with microcystic edema. Repeat ocular surface cultures and PCR were negative. Given the negative results of extensive infectious etiology testing, we prescribed oral prednisone (40 mg/d) for presumed undifferentiated necrotizing anterior scleritis and keratitis.

One week later, corneal inflammation worsened (Figure, panel D). Clinical deterioration on systemic steroids continued to raise suspicion for ocular infection; we stopped steroid treatments. Again, cultures and PCR remained negative. Without prednisone, the patient's limbal infiltrates worsened, with progressive corneal haze. White corneal endothelial plaques appeared. We performed anterior chamber paracentesis for cultures, viral PCR, and an RNA deep-sequencing (RNA-seq) protocol previously described (1). The patient's scleritis, keratitis, and anterior uveitis worsened (Figure, panels E, F). Right eye vision decreased to hand motion only. We performed a diagnostic scleral and corneal biopsy and initiated

EID cannot ensure accessibility for supplementary materials supplied by authors. Readers who have difficulty accessing supplementary content should contact the authors for assistance.

Enhanced Adenovirus Vaccine Safety Surveillance in Military Setting, United States

Appendix

Adenovirus vaccine postvaccination signs and symptoms reporting tool (day 0 is day of vaccination).

Symptom (Y/N)	Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9	Day 10
Fever (subjective or measured at >100.5°F)											
Headache											
Fatigue											
Body aches or joint pains											
Cough											
Shortness of breath											
Sore throat											
Nasal congestion or runny nose											
Nausea											
Vomiting											
Diarrhea											
Abdominal pain											
Burning with urination											
Blood in urine											
New rash											
Numbness or tingling in hands or feet											
Inability or increasing weakness in arms or legs											